Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T05:42:49.643Z Has data issue: false hasContentIssue false
  • English
  • Français

MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses

Published online by Cambridge University Press:  02 December 2014

Sarah A. Morrow ,
Lynn McEwan ,
Katayoun Alikhani ,
Christopher Hyson  and
Marcelo Kremenchutzky
Sarah A. Morrow*
Affiliation:
University of Western Ontario, London, Ontario
Lynn McEwan
Affiliation:
University of Western Ontario, London, Ontario
Katayoun Alikhani
Affiliation:
Multiple Sclerosis Clinic, Foothills Hospital, Calgary, Alberta, Canada
Christopher Hyson
Affiliation:
University of Western Ontario, London, Ontario
Marcelo Kremenchutzky
Affiliation:
University of Western Ontario, London, Ontario
*
University of Western Ontario, LSHC-UH B10-118, 339 Windermere Rd, London, Ontario, N6G 1W8, Canada. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Multiple Sclerosis is characterized by relapses separated by periods of relative quiescence. High dose intravenous corticosteroid pulses for three to five days is the current standard for the treatment of acute relapses, but recent evidence supports the use of equivalent doses of oral therapy as an alternative. The highest single dose preparation of oral prednisone is a 50mg tablet, requiring patients to take 25 tablets a day. Questions regarding compliance with this oral regimen have been raised.

Objectives:

To determine whether MS patients are complaint with 1250mg of oral prednisone daily for acute relapses.

Methods:

Between November 2008 and December 2009, all patients diagnosed with an acute relapse in the London (Ontario) MS clinic were prospectively identified. If treatment with oral prednisone was initiated, subjects were given a survey to be mailed anonymously to the clinic.

Results:

Sixtyeight MS relapses were diagnosed and treated with corticosteroids in 66 patients of which 60 (58 subjects) were treated with 1250mg prednisone. Fifty-three (91.4%) surveys were returned. The reported compliance rate was high at 94.3% (50/53) with only one patient reporting being unable to take all the required pills due to intolerance. Most subjects (43, 86.0%) encountered at least one side effect, most commonly insomnia, mood changes and increased appetite. Two thirds of subjects (69.8%) indicated a preference for oral medication for future relapses.

Conclusion:

High dose (1250mg) oral prednisone is an acceptable therapy to MS patients for the treatment of acute relapses with a high rate of compliance.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 3 , May 2012 , pp. 352 - 354
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1Beck, CA, Metz, LM, Svenson, LW, Patten, SB.Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005;11: 516–19.Google Scholar
2Murray, TJ.Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–7.Google Scholar
3Confavreux, C, Vukusic, S, Moreau, T, Adeleine, P.Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.Google Scholar
4Beck, RW, Cleary, PA, Backlund, JC.The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthal. 1994;101:1771–8.CrossRefGoogle ScholarPubMed
5Sellebjerg, F, Barnes, D, Filippini, G, et al.EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12:939–46.CrossRefGoogle ScholarPubMed
6Goodin, DS, Frohman, EM, Garmany, GP Jr, et al.Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–78.Google Scholar
7Metz, LM, Harris, CJ, Moore, A.MS patients’ choice of oral rather than IV steroid therapy results in savings to health care system. International Journal of MS Care (serial on the internet) 2000; March (cited 2010 Sept). Available at www.mscare.orgGoogle Scholar
8Martinelli, V, Rocca, MA, Annovazzi, P, et al.A short-term randomized MRI study of high-dose oral vs. intravenous methylprednisolone in MS. Neurology. 2009;73:1842–8.Google Scholar
9Morrow, SA, Stoian, CA, Dmitrovic, J, Chan, SC, Metz, LM.The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079–80.Google Scholar
10Burton, JM, O’Connor, PW, Hohol, M, Beyene, J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009:CD006921.Google Scholar
11Metz, LM, Sabuda, D, Hilsden, RJ, Enns, R, Meddings, JB.Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology. 1999;53:2093–6.CrossRefGoogle ScholarPubMed
12Beck, RW, Cleary, PA, Anderson, MM Jr., et al.A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–8.CrossRefGoogle ScholarPubMed
13Trobe, JD, Sieving, PC, Guire, KE, Fendrick, AM.The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999;106:2047–53.Google Scholar
14Tse, FL, Welling, PG.Relative bioavailability of prednisone and prednisolone in man. J Pharm Pharmacol. 1979;31:492–3.Google Scholar
15Morrow, SA, Metz, LM, Kremenchutzky, M.High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci. 2009;36:213–15.Google Scholar
16Goff, DC, Hill, M, Freudenreich, O.Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;72:e13.CrossRefGoogle ScholarPubMed
17Katon, WJ.Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:7–23.CrossRefGoogle ScholarPubMed
18World Health Organization (WHO). Adherence to long-term therapies. Evidence for action. 2003. Available at http://whqlibdoc.who.int/publications/2003/9241545992.pdfGoogle Scholar
19Hohl, CM, Abu-Laban, RB, Brubacher, JR, et al.Adherence to emergency department discharge prescriptions. CJEM 2009;11: 131–8.Google Scholar
20Llor, C, Hernandez, S, Sierra, N, Moragas, A, Hernandez, M, Bayona, C.Association between use of rapid antigen detection tests and adherence to antibiotics in suspected streptococcal pharyngitis. Scand J Prim Health Care. 2010;28:12–17.Google Scholar